Alireza  Javadi net worth and biography

Alireza Javadi Biography and Net Worth

Chief Technical Officer of Rani Therapeutics

With over 15 years of technical and operational leadership within the medical device and life science industry, Alireza stands at the forefront of Manufacturing Scale up, Continuous Improvement and Process Development Optimization. As Vice President, Technical Operations at Rani Therapeutics, Alireza has responsibility for Rani's technical R&D, manufacturing and automation teams and has spearheaded improvements in critical manufacturing processes, boosting device manufacturing yield and most notably setting up supply chain and manufacturing scale up system, which has resulted in a 50% reduction in materials cost and a 20% improvement in yield efficiency. Alireza's career began at Wisconsin Institute for Discovery, where his keen insights and curiosity led to the discovery and development of novel nanoparticles for targeted anti-cancer drug delivery. He spent the next decade of his career in various technical and operational leadership roles at prominent Research or Contract Development and Manufacturing Organizations (CDMO) Including Wisconsin Institute for Discovery and Cretex Medical. Alireza holds a PhD in Materials Science from University of Wisconsin and a Master's degree in Advanced Engineering Materials from Chalmers University in Sweden.

What is Alireza Javadi's net worth?

The estimated net worth of Alireza Javadi is at least $8.28 thousand as of March 27th, 2026. Mr. Javadi owns 9,689 shares of Rani Therapeutics stock worth more than $8,276 as of August 28th. This net worth estimate does not reflect any other investments that Mr. Javadi may own. Learn More about Alireza Javadi's net worth.

How do I contact Alireza Javadi?

The corporate mailing address for Mr. Javadi and other Rani Therapeutics executives is , , . Rani Therapeutics can also be reached via phone at 408-457-3700 and via email at [email protected]. Learn More on Alireza Javadi's contact information.

Has Alireza Javadi been buying or selling shares of Rani Therapeutics?

Alireza Javadi has not been actively trading shares of Rani Therapeutics in the last ninety days. Most recently, Alireza Javadi sold 386 shares of the business's stock in a transaction on Friday, March 27th. The shares were sold at an average price of $0.78, for a transaction totalling $301.08. Following the completion of the sale, the insider now directly owns 9,689 shares of the company's stock, valued at $7,557.42. Learn More on Alireza Javadi's trading history.

Are insiders buying or selling shares of Rani Therapeutics?

In the last year, Rani Therapeutics insiders bought shares 3 times. They purchased a total of 2,154,334 shares worth more than $1,300,040.40. In the last year, insiders at the sold shares 3 times. They sold a total of 5,923,386 shares worth more than $15,714,731.08. The most recent insider tranaction occured on July, 21st when Director Mir A Imran bought 36,000 shares worth more than $24,840.00. Insiders at Rani Therapeutics own 26.7% of the company. Learn More about insider trades at Rani Therapeutics.

Information on this page was last updated on 7/21/2026.

Alireza Javadi Insider Trading History at Rani Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/27/2026Sell386$0.78$301.089,689View SEC Filing Icon  
See Full Table

Alireza Javadi Buying and Selling Activity at Rani Therapeutics

This chart shows Alireza Javadi's buying and selling at Rani Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Rani Therapeutics Company Overview

Rani Therapeutics logo
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.
Read More

Today's Range

Now: $0.85
Low: $0.85
High: $0.86

50 Day Range

MA: $0.78
Low: $0.63
High: $0.92

2 Week Range

Now: $0.85
Low: $0.44
High: $3.87

Volume

67,361 shs

Average Volume

995,417 shs

Market Capitalization

$117.93 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.78